Table 1.
Summary of reviewed consensus statements and guidelines regarding the use of infliximab
| Medical specialty | Study, year published (reference) | Paper | Country |
|---|---|---|---|
| Gastroenterology | Consensus statement | ||
| ECCO, 2006 [6] | European evidence based consensus on the diagnosis and management of Crohn's disease: current management | Europe | |
| AGA, 2007 [4] | American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease | International | |
| Guidelines | |||
| Hommes et al., 2006 [7] | Guidelines for treatment with infliximab for Crohn's disease | The Netherlands | |
| Panaccione et al., 2004 [8] | Canadian Association of Gastroenterology clinical practice guidelines: The use of infliximab in Crohn's disease | Canada | |
| Rheumatology | Consensus statement | ||
| Furst et al., 2008 [9] | Updated consensus statement on biological agents for the treatment of rheumatic diseases | International | |
| Braun et al., 2006 [18] | First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis | International | |
| NVR, 2004 [19] | Statement on the application of TNF-blockade in the treatment of ankylosing spondylitis | The Netherlands | |
| CRA, 2003 [57] | Canadian rheumatology association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis | Canada | |
| Guidelines | |||
| NICE, 2007 [11] | NICE technology appraisal guidance 130. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis | UK | |
| NVR, 2003 [12] | Guideline: Application of anti-TNF blockers in the treatment of rheumatoid arthtritis | The Netherlands | |
| FSR, 2007 [13] | Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis | France | |
| JCR, 2007 [14] | Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis | Japan | |
| ACR, 2008 [17] | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis | USA | |
| NICE, 2008 [23] | NICE technology appraisal guidance 143. Adalimumab, etanercept and infliximab for ankylosing spondylitis | UK | |
| NICE, 2007 [24] | NICE technology appraisal guidance 104. Etanercept and infliximab for the treatment of adults with psoriatic arthritis | UK | |
| BSR, 2005 [16] | Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) | UK | |
| BSR, 2005 [21] | BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology | UK | |
| FSR, 2007 [22] | Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update | France | |
| Dermatology | Consensus statement | ||
| Reich et al., 2008 [25] | Recommendations for the long-term treatment of psoriasis with infliximab: A dermatology expert group consensus | Europe and Canada | |
| Sterry et al., 2004 [58] | Biological therapies in the systemic management of psoriasis: International Consensus Conference | International | |
| Guidelines | |||
| BAD, 2005 [26] | British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 | UK | |
| NVDV, 2005 [27] | Guideline: Application of biologicals in the treatment of psoriasis | The Netherlands | |
| AAD, 2008 [36] | Guidelines of care for the management of psoriasis and psoriatic arthritis – Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. | USA | |
| NICE, 2008 [59] | Infliximab for the treatment of adults with psoriasis | UK | |
| AAD, 2008 [60] | Guidelines of care for the management of psoriasis and psoriatic arthritis – Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics | USA |
AAD, American Academy of Dermatology; ACR, American College of Rheumatology; AGA, American Gastroenterological Association; BAD, British Association of Dermatologists; BSR, The British Society for Rheumatology; CRA, Canadian Rheumatology Association; ECCO, European Crohn's and Colitis Organisation; FSR, French Society of Rheumatology; JCR, Japan College of Rheumatology; NICE, National Institute for Clinical Excellence; NVDV, Nederlandse Vereniging voor Dermatologie en Verenologie; NVR, Nederlandse Vereniging voor Reumatologie.